Fox Chase Cancer Center News

PHILADELPHIA (May 20, 2020) — According to the 2019 national survey, 48.7 percent of oncology physician assistants reported burnout, as opposed to 34.8 percent in 2015.

PHILADELPHIA (May 18, 2020)—Fox Chase was recognized for its use of the Monarch Platform, a technology that features a familiar controller-like interface that physicians use to navigate a flexible robotic endoscope to the periphery of the lung. The technology improves reach, vision, and control.

PHILADELPHIA (May 14, 2020) – May is Skin Cancer Prevention Month.  The two most common types of skin cancers, basal cell and squamous cell skin cancers, are usually very treatable and most commonly found in areas exposed to the sun.

PHILADELPHIA (May 11, 2020) — Combination strategies targeting the immune checkpoint pathway from multiple angles may be the key. A recent study suggested the benefit of two immune checkpoint drugs, which showed promising response in this rare cancer.

PHILADELPHIA (May 6, 2020)—A study on tumor factors increasing the risk of a patient’s cancer spreading to other areas of the body following treatment with stereotactic body radiation therapy (SBRT) alone in patients with lung cancer.

PHILADELPHIA (May 4, 2020)—As COVID-19 continues to put a strain on hospitals, numerous restaurants, companies, and individuals have stepped up to donate food and other items to health care workers on the frontlines of the pandemic.

Fox Chase Cancer Center has received multiple donations from the community as staff continue to go above and beyond in caring for patients.

Philadelphia Magazine named forty-four Fox Chase Cancer Center physicians to their “Top Doctors” list for 2020. 

PHILADELPHIA (April 30, 2020)—In a study published today, researchers at Fox Chase Cancer Center were able to determine that the BRCA1 gene has two distinct and equally important functions in the process of DNA repair, a finding which sheds light on the response and resistance of cancers to certain chemotherapies. The findings have implications for cancer therapy because drugs known as PARP inhibitors successfully treat BRCA1-mutant breast and ovarian cancers